Cancer Treatment In 7 Minutes: UK's Health Service To Rollout Roche's Tencentriq Injection Cutting Treatment Time
Portfolio Pulse from Vandana Singh
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved the National Health Service (NHS) to implement a seven-minute injection for cancer patients using Roche Holdings AG's Tencentriq (atezolizumab). The new method is quicker and more comfortable than the previous 30-minute to one-hour intravenous drug transfusion. The change will benefit approximately 3,600 patients annually in England. The treatment will come at no additional cost to the NHS due to an existing agreement with Roche.
August 30, 2023 | 3:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roche's Tencentriq has been approved for a quicker and more comfortable injection method for cancer treatment in the UK. This could potentially increase the usage of the drug, benefiting Roche.
The approval of Roche's Tencentriq for a quicker and more comfortable method of cancer treatment could potentially increase the usage of the drug. This is beneficial for Roche as it could lead to increased sales and revenue. The fact that the treatment comes at no additional cost to the NHS due to an existing agreement with Roche also ensures that the financial impact on Roche is positive.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100